Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Decision Resources Group
Over Three-Quarters of Physicians View Ophthotech's Fovista as an Emerging Therapy with High Potential Value for Wet AMD, According to Findings from Decision Resources Group
BURLINGTON, Mass., Aug. 14, 2014 /PRNewswire/ -- Decision Resources Group finds that physician-reported patient shares for Regeneron's Eylea, as well as the other major anti-vascular endothelial growth factor (VEGF) agents Genentech/Roche's Avastin and Genentech/Roche's Lucentis, have now stabilized among wet age-related macular degeneration (AMD) patients, following significant movement after the 2011 U.S. launch of Eylea. Although off-label compounded Avastin, with its low cost, continues to be the U.S. patient share leader and most-preferred option for wet AMD, Eylea slightly edges out Lucentis as the preferred second-line treatment approach-driven by physicians' positive perceptions of Eylea's efficacy and its convenient dosing frequency.
Other key findings from the TreatmentTrends: Dry/Wet AMD 2014 (US) report:
Comments from Decision Resources Group Analyst Emma McFadden, Ph.D.:
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
©2012 PR Newswire. All Rights Reserved.
7831 N. Business Park Drive